Table 3.
Severe and fatal infectious events with VEGFR-TKIs by specific types
| Infectious events, n/total, n
|
RR (95% CI) | P-value | ||
|---|---|---|---|---|
| VEGFR-TKIs | Control | |||
| Severe infections | ||||
| Unspecified | 57/1,125 | 28/834 | 1.53 (0.98–2.39) | 0.062 |
| Febrile neutropenia | 298/4,025 | 195/4,049 | 1.57 (1.30–1.88) | ,0.001 |
| Pneumonia | 102/6,273 | 48/5,172 | 1.79 (1.29–2.49) | ,0.001 |
| Fever | 10/844 | 0/528 | 5.35 (1.47–19.51) | 0.011 |
| Sepsis | 17/2,097 | 3/1,533 | 3.68 (1.51–8.99) | 0.004 |
| Fatal infections | ||||
| Pneumonia | 36/4,685 | 24/3,871 | 1.34 (0.80–2.25) | 0.26 |
| Sepsis | 16/1,866 | 3/1,434 | 3.66 (1.47–9.13) | 0.005 |
| Overall | 52/4,923 | 27/4,111 | 1.78 (1.13–2.81) | 0.013 |
Abbreviations: VEGFR-TKIs, vascular endothelial growth factor receptor tyrosine kinase inhibitors; RR, relative risk; CI, confidence interval.